HS-130: The first allogeneic, off-the-shelf cell therapy that delivers localized OX40-mediated co-stimulation to enhance T-cell activation
HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses.
Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fc via cell-based delivery compared to systemic administration of an OX40 agonist antibody in combination with HS-110. A phase 1 clinical trial has been initiated.
| Program | Mechanism of Action (Modality) |
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
HS-130 |
OX40L (Cell Therapy) |
SOLID TUMORS |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|